Logo

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Share this

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • The companies will collaborate to develop- manufacture- and distribute AT-527 to combat COVID-19. If approved- Atea will be responsible for distributing the treatment option in the US- with the option to request Genentech’s support- and Roche will be responsible for distribution outside the US
  • The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21- that explores the potential use in patients outside of the hospital setting. Additionally- AT-527 may be developed for post-exposure prophylactic settings
  • AT-527 is an investigational- oral- purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus- including human flavivirus and coronavirus

 ­ Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions